These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 17911587

  • 1. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.
    Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, Gauldie J, Bramson J, Wan Y.
    J Immunol; 2007 Oct 15; 179(8):5024-32. PubMed ID: 17911587
    [Abstract] [Full Text] [Related]

  • 2. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.
    J Immunol; 2004 Feb 15; 172(4):2126-36. PubMed ID: 14764678
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
    Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ.
    J Immunol; 2000 Dec 01; 165(11):6244-51. PubMed ID: 11086059
    [Abstract] [Full Text] [Related]

  • 5. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
    Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ.
    J Immunol; 2002 Nov 01; 169(9):4928-35. PubMed ID: 12391205
    [Abstract] [Full Text] [Related]

  • 6. Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential.
    Kelleher M, Beverley PC.
    J Immunol; 2001 Dec 01; 167(11):6247-55. PubMed ID: 11714787
    [Abstract] [Full Text] [Related]

  • 7. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
    Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y.
    J Immunol; 2004 Jan 15; 172(2):776-86. PubMed ID: 14707047
    [Abstract] [Full Text] [Related]

  • 8. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J.
    Clin Immunol; 2004 Jul 15; 112(1):35-44. PubMed ID: 15207780
    [Abstract] [Full Text] [Related]

  • 9. A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.
    Hunzeker JT, Elftman MD, Mellinger JC, Princiotta MF, Bonneau RH, Truckenmiller ME, Norbury CC.
    J Immunol; 2011 Jan 01; 186(1):183-94. PubMed ID: 21098225
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
    Xie Y, Zhang H, Li W, Deng Y, Munegowda MA, Chibbar R, Qureshi M, Xiang J.
    J Immunol; 2010 Nov 01; 185(9):5268-78. PubMed ID: 20881190
    [Abstract] [Full Text] [Related]

  • 11. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
    Krishnan L, Sad S, Patel GB, Sprott GD.
    J Immunol; 2000 Nov 01; 165(9):5177-85. PubMed ID: 11046050
    [Abstract] [Full Text] [Related]

  • 12. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E, Celis E.
    J Immunol; 2000 Jul 01; 165(1):539-47. PubMed ID: 10861094
    [Abstract] [Full Text] [Related]

  • 13. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P.
    J Immunol; 2000 Sep 01; 165(5):2651-6. PubMed ID: 10946294
    [Abstract] [Full Text] [Related]

  • 14. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
    Vabulas RM, Pircher H, Lipford GB, Häcker H, Wagner H.
    J Immunol; 2000 Mar 01; 164(5):2372-8. PubMed ID: 10679072
    [Abstract] [Full Text] [Related]

  • 15. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
    del Rio ML, Rodriguez-Barbosa JI, Kremmer E, Förster R.
    J Immunol; 2007 Jun 01; 178(11):6861-6. PubMed ID: 17513734
    [Abstract] [Full Text] [Related]

  • 16. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P, Brocker T.
    J Immunol; 2003 Mar 15; 170(6):2817-23. PubMed ID: 12626531
    [Abstract] [Full Text] [Related]

  • 17. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS.
    Exp Mol Med; 2004 Oct 31; 36(5):428-43. PubMed ID: 15557815
    [Abstract] [Full Text] [Related]

  • 18. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A, Gilboa E.
    J Exp Med; 1995 Jul 01; 182(1):255-60. PubMed ID: 7540653
    [Abstract] [Full Text] [Related]

  • 19. The exocytosis of lytic granules is impaired in Vti1b- or Vamp8-deficient CTL leading to a reduced cytotoxic activity following antigen-specific activation.
    Dressel R, Elsner L, Novota P, Kanwar N, Fischer von Mollard G.
    J Immunol; 2010 Jul 15; 185(2):1005-14. PubMed ID: 20543108
    [Abstract] [Full Text] [Related]

  • 20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.